The balancing act of GABAergic synapse organizers

Trends in Molecular Medicine

Volumn 21, Issue 4, 2015, Pages 256-268

  Ko, Jaewon ^a,b   Choii, Gayoung ^a   Um, Ji Won ^a,b  

^a Yonsei University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Excitation inhibition balance; GABA; Inhibitory synapse; Synapse organizer; Synaptic adhesion

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; CELL ADHESION MOLECULE; CYTOSKELETON PROTEIN; SCAFFOLD PROTEIN; TRANSCRIPTION FACTOR; 4 AMINOBUTYRIC ACID; GABAERGIC RECEPTOR AFFECTING AGENT;

BRAIN DISEASE; BRAIN FUNCTION; CELL FUNCTION; CELL MATURATION; GABAERGIC SYSTEM; GABAERGIC TRANSMISSION; HUMAN; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NONHUMAN; POSTSYNAPTIC DENSITY; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SYNAPSE; SYNAPTIC TRANSMISSION; ANIMAL; BRAIN; DISEASE MODEL; DRUG EFFECTS; NERVE CELL; PHYSIOLOGY;

MAMMALIA;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; GABA AGENTS; GAMMA-AMINOBUTYRIC ACID; HUMANS; NEURONS; SYNAPSES; SYNAPTIC TRANSMISSION;

EID: 84925594917     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2015.01.004     Document Type: Review

References (135)

1. Harris K.M., Weinberg R.J. Ultrastructure of synapses in the mammalian brain. Cold Spring Harb. Perspect. Biol. 2012, 4:a005587.
2. Brose N., et al. Synaptopathy: dysfunction of synaptic function?. Biochem. Soc. Trans. 2010, 38:443-444.
3. Mailman R.B., Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?. Curr. Pharm. Des. 2010, 16:488-501.
4. Ghosh A., et al. Drug discovery for autism spectrum disorder: challenges and opportunities. Nat. Rev. Drug Discov. 2013, 12:777-790.
5. Delorme R., et al. Progress toward treatments for synaptic defects in autism. Nat. Med. 2013, 19:685-694.
6. Heller E.A., et al. The biochemical anatomy of cortical inhibitory synapses. PLoS ONE 2012, 7:e39572.
7. Kang Y., et al. A combined transgenic proteomic analysis and regulated trafficking of neuroligin-2. J. Biol. Chem. 2014, 289:29350-29364.
8. Gupta A., et al. Organizing principles for a diversity of GABAergic interneurons and synapses in the neocortex. Science 2000, 287:273-278.
9. Arancibia-Carcamo I.L., Moss S.J. Molecular organization and assembly of the central inhibitory postsynapse. Results Probl. Cell Differ. 2006, 43:25-47.
10. Missler M., et al. Synaptic cell adhesion. Cold Spring Harb. Perspect. Biol. 2012, 4:a005694.
11. Varoqueaux F., et al. Neuroligin 2 is exclusively localized to inhibitory synapses. Eur. J. Cell Biol. 2004, 83:449-456.
12. Chubykin A.A., et al. Activity-dependent validation of excitatory versus inhibitory synapses by neuroligin-1 versus neuroligin-2. Neuron 2007, 54:919-931.
13. Ko J., et al. Neuroligin-1 performs neurexin-dependent and neurexin-independent functions in synapse validation. EMBO J. 2009, 28:3244-3255.
14. Chih B., et al. Alternative splicing controls selective trans-synaptic interactions of the neuroligin-neurexin complex. Neuron 2006, 51:171-178.
15. Patrizi A., et al. Synapse formation and clustering of neuroligin-2 in the absence of GABAA receptors. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:13151-13156.
16. Poulopoulos A., et al. Neuroligin 2 drives postsynaptic assembly at perisomatic inhibitory synapses through gephyrin and collybistin. Neuron 2009, 63:628-642.
17. Antonelli R., et al. Pin1-dependent signalling negatively affects GABAergic transmission by modulating neuroligin2/gephyrin interaction. Nat. Commun. 2014, 5:5066.
18. Gibson J.R., et al. Neuroligin-2 deletion selectively decreases inhibitory synaptic transmission originating from fast-spiking but not from somatostatin-positive interneurons. J. Neurosci. 2009, 29:13883-13897.
19. Hoon M., et al. Neuroligin 2 controls the maturation of GABAergic synapses and information processing in the retina. J. Neurosci. 2009, 29:8039-8050.
20. Jedlicka P., et al. Increased dentate gyrus excitability in neuroligin-2-deficient mice in vivo. Cereb. Cortex 2011, 21:357-367.
21. Lee K., et al. MDGAs interact selectively with neuroligin-2 but not other neuroligins to regulate inhibitory synapse development. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:336-341.
22. Pettem K.L., et al. Interaction between autism-linked MDGAs and neuroligins suppresses inhibitory synapse development. J. Cell Biol. 2013, 200:321-336.
23. Litwack E.D., et al. Identification and characterization of two novel brain-derived immunoglobulin superfamily members with a unique structural organization. Mol. Cell. Neurosci. 2004, 25:263-274.
24. Wills Z.P., et al. The nogo receptor family restricts synapse number in the developing hippocampus. Neuron 2012, 73:466-481.
25. Glynn M.W., et al. MHCI negatively regulates synapse density during the establishment of cortical connections. Nat. Neurosci. 2011, 14:442-451.
26. Fairless R., et al. Polarized targeting of neurexins to synapses is regulated by their C-terminal sequences. J. Neurosci. 2008, 28:12969-12981.
27. Fu Y., Huang Z.J. Differential dynamics and activity-dependent regulation of alpha- and beta-neurexins at developing GABAergic synapses. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:22699-22704.
28. 2+ channels to synaptic vesicle exocytosis. Nature 2003, 423:939-948.
29. Kang Y., et al. Induction of GABAergic postsynaptic differentiation by alpha-neurexins. J. Biol. Chem. 2008, 283:2323-2334.
30. Treutlein B., et al. Cartography of neurexin alternative splicing mapped by single-molecule long-read mRNA sequencing. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:1291-1299.
31. Futai K., et al. Specific trans-synaptic interaction with inhibitory interneuronal neurexin underlies differential ability of neuroligins to induce functional inhibitory synapses. J. Neurosci. 2013, 33:3612-3623.
32. Ko J. The leucine-rich repeat superfamily of synaptic adhesion molecules: LRRTMs and Slitrks. Mol. Cells 2012, 34:335-340.
33. Um J.W., Ko J. LAR-RPTPs: synaptic adhesion molecules that shape synapse development. Trends Cell Biol. 2013, 6:1096-1109.
34. Takahashi H., Craig A.M. Protein tyrosine phosphatases PTPdelta, PTPsigma, and LAR: presynaptic hubs for synapse organization. Trends Neurosci. 2013, 36:522-534.
35. Yim Y.S., et al. Slitrks control excitatory and inhibitory synapse formation with LAR receptor protein tyrosine phosphatases. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:4057-4062.
36. Takahashi H., et al. Selective control of inhibitory synapse development by Slitrk3-PTPdelta trans-synaptic interaction. Nat. Neurosci. 2012, 15:389-398.
37. Uetani N., et al. Impaired learning with enhanced hippocampal long-term potentiation in PTPdelta-deficient mice. EMBO J. 2000, 19:2775-2785.
38. Mattheisen M., et al. Genome-wide association study in obsessive-compulsive disorder: results from the OCGAS. Mol. Psychiatry 2014, Published online May 13, 2014. http://dx.doi.org/10.1038/mp.2014.43.
39. Um J.W., et al. Structural basis for LAR-RPTP/Slitrk complex-mediated synaptic adhesion. Nat. Commun. 2014, 5:5423.
40. Hansen M., Walmod P.S. IGSF9 family proteins. Neurochem. Res. 2013, 38:1236-1251.
41. Mishra A., et al. The protein dendrite arborization and synapse maturation 1 (Dasm-1) is dispensable for dendrite arborization. Mol. Cell. Biol. 2008, 28:2782-2791.
42. Mishra A., et al. Genetic evidence for the adhesion protein IgSF9/Dasm1 to regulate inhibitory synapse development independent of its intracellular domain. J. Neurosci. 2014, 34:4187-4199.
43. Woo J., et al. The adhesion protein IgSF9b is coupled to neuroligin 2 via S-SCAM to promote inhibitory synapse development. J. Cell Biol. 2013, 201:929-944.
44. Beesley P.W., et al. The Neuroplastin adhesion molecules: key regulators of neuronal plasticity and synaptic function. J. Neurochem. 2014, 131:268-283.
45. Sarto-Jackson I., et al. The cell adhesion molecule neuroplastin-65 is a novel interaction partner of gamma-aminobutyric acid type A receptors. J. Biol. Chem. 2012, 287:14201-14214.
46. Herrera-Molina R., et al. Structure of excitatory synapses and GABAA receptor localization at inhibitory synapses are regulated by neuroplastin-65. J. Biol. Chem. 2014, 289:8973-8988.
47. Um J.W., et al. Calsyntenins function as synaptogenic adhesion molecules in concert with neurexins. Cell Rep. 2014, 6:1096-1109.
48. Pettem K.L., et al. The specific alpha-neurexin interactor calsyntenin-3 promotes excitatory and inhibitory synapse development. Neuron 2013, 80:113-128.
49. Kuzirian M.S., et al. The class 4 semaphorin Sema4D promotes the rapid assembly of GABAergic synapses in rodent hippocampus. J. Neurosci. 2013, 33:8961-8973.
50. Raissi A.J., et al. Sema4D localizes to synapses and regulates GABAergic synapse development as a membrane-bound molecule in the mammalian hippocampus. Mol. Cell. Neurosci. 2013, 57:23-32.
51. Chen A.I., et al. TrkB (tropomyosin-related kinase B) controls the assembly and maintenance of GABAergic synapses in the cerebellar cortex. J. Neurosci. 2011, 31:2769-2780.
52. Wuchter J., et al. A comprehensive small interfering RNA screen identifies signaling pathways required for gephyrin clustering. J. Neurosci. 2012, 32:14821-14834.
53. Terauchi A., et al. Distinct FGFs promote differentiation of excitatory and inhibitory synapses. Nature 2010, 465:783-787.
54. Lee C.H., et al. Neurogenesis is enhanced and mossy fiber sprouting arises in FGF7-deficient mice during development. Mol. Cell. Neurosci. 2012, 51:61-67.
55. Sheng M., Kim E. The postsynaptic organization of synapses. Cold Spring Harb. Perspect. Biol. 2011, 3:a005678.
56. Tyagarajan S.K., Fritschy J.M. Gephyrin: a master regulator of neuronal function?. Nat. Rev. Neurosci. 2014, 15:141-156.
57. Specht C.G., et al. Quantitative nanoscopy of inhibitory synapses: counting gephyrin molecules and receptor binding sites. Neuron 2013, 79:308-321.
58. Korber C., et al. Effects of distinct collybistin isoforms on the formation of GABAergic synapses in hippocampal neurons. Mol. Cell. Neurosci. 2012, 50:250-259.
59. Papadopoulos T., Soykan T. The role of collybistin in gephyrin clustering at inhibitory synapses: facts and open questions. Front. Cell. Neurosci. 2011, 5:11.
60. Fukaya M., et al. SynArfGEF is a guanine nucleotide exchange factor for Arf6 and localizes preferentially at post-synaptic specializations of inhibitory synapses. J. Neurochem. 2011, 116:1122-1137.
61. Sakagami H., et al. Distinct synaptic localization patterns of brefeldin A-resistant guanine nucleotide exchange factors BRAG2 and BRAG3 in the mouse retina. J. Comp. Neurol. 2013, 521:860-876.
62. Lin Y., et al. Activity-dependent regulation of inhibitory synapse development by Npas4. Nature 2008, 455:1198-1204.
63. Yun J., et al. Neuronal Per Arnt Sim (PAS) domain protein 4 (NPAS4) regulates neurite outgrowth and phosphorylation of synapsin I. J. Biol. Chem. 2013, 288:2655-2664.
64. Sim S., et al. Increased cell-intrinsic excitability induces synaptic changes in new neurons in the adult dentate gyrus that require Npas4. J. Neurosci. 2013, 33:7928-7940.
65. Zhang Z., et al. Hippocampal expression of aryl hydrocarbon receptor nuclear translocator 2 and neuronal PAS domain protein 4 in a rat model of depression. Neurol. Sci. 2014, 35:277-282.
66. Guidotti G., et al. Developmental influence of the serotonin transporter on the expression of npas4 and GABAergic markers: modulation by antidepressant treatment. Neuropsychopharmacology 2012, 37:746-758.
67. Castillo P.E., et al. Long-term plasticity at inhibitory synapses. Curr. Opin. Neurobiol. 2011, 21:328-338.
68. Maffei A. The many forms and functions of long term plasticity at GABAergic synapses. Neural Plast. 2011, 2011:254724.
69. Tang Z.Q., et al. Activation of synaptic group II metabotropic glutamate receptors induces long-term depression at GABAergic synapses in CNS neurons. J. Neurosci. 2013, 33:15964-15977.
70. Dacher M., et al. A-kinase anchoring protein-calcineurin signaling in long-term depression of GABAergic synapses. J. Neurosci. 2013, 33:2650-2660.
71. Castillo P.E., et al. Endocannabinoid signaling and synaptic function. Neuron 2012, 76:70-81.
72. Sons M.S., et al. alpha-Neurexins are required for efficient transmitter release and synaptic homeostasis at the mouse neuromuscular junction. Neuroscience 2006, 138:433-446.
73. Foldy C., et al. Autism-associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling. Neuron 2013, 78:498-509.
74. Pribiag H., et al. Dystroglycan mediates homeostatic synaptic plasticity at GABAergic synapses. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:6810-6815.
75. Levi S., et al. Dystroglycan is selectively associated with inhibitory GABAergic synapses but is dispensable for their differentiation. J. Neurosci. 2002, 22:4274-4285.
76. Born G., et al. Modulation of synaptic function through the alpha-neurexin-specific ligand neurexophilin-1. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:E1274-E1283.
77. Reissner C., et al. Dystroglycan binding to alpha-neurexin competes with neurexophilin-1 and neuroligin in the brain. J. Biol. Chem. 2014, 289:27585-27603.
78. Paluszkiewicz S.M., et al. Fragile X syndrome: the GABAergic system and circuit dysfunction. Dev. Neurosci. 2011, 33:349-364.
79. Ramamoorthi K., Lin Y. The contribution of GABAergic dysfunction to neurodevelopmental disorders. Trends Mol. Med. 2011, 17:452-462.
80. Bloodgood B.L., et al. The activity-dependent transcription factor NPAS4 regulates domain-specific inhibition. Nature 2013, 503:121-125.
81. Ploski J.E., et al. The neuronal PAS domain protein 4 (Npas4) is required for new and reactivated fear memories. PLoS ONE 2011, 6:e23760.
82. Spiegel I., et al. Npas4 regulates excitatory-inhibitory balance within neural circuits through cell-type-specific gene programs. Cell 2014, 157:1216-1229.
83. Schousboe A., et al. The GABA synapse as a target for antiepileptic drugs: a historical overview focused on GABA transporters. Neurochem. Res. 2014, 39:1980-1987.
84. Bialer M., White H.S. Key factors in the discovery and development of new antiepileptic drugs. Nat. Rev. Drug Discov. 2010, 9:68-82.
85. Lanctot K.L., et al. Behavioral correlates of GABAergic disruption in Alzheimer's disease. Int. Psychogeriatr. 2007, 19:151-158.
86. Zoghbi H.Y., Bear M.F. Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. Cold Spring Harb. Perspect. Biol. 2012, 4:a009886.
87. Won H., et al. Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function. Nature 2012, 486:261-265.
88. Bateup H.S., et al. Excitatory/inhibitory synaptic imbalance leads to hippocampal hyperexcitability in mouse models of tuberous sclerosis. Neuron 2013, 78:510-522.
89. Rudolph U., Knoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat. Rev. Drug Discov. 2011, 10:685-697.
90. Blundell J., et al. Increased anxiety-like behavior in mice lacking the inhibitory synapse cell adhesion molecule neuroligin 2. Genes Brain Behav. 2009, 8:114-126.
91. Hoon M., et al. Neuroligin-4 is localized to glycinergic postsynapses and regulates inhibition in the retina. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:3053-3058.
92. Tabuchi K., et al. A neuroligin-3 mutation implicated in autism increases inhibitory synaptic transmission in mice. Science 2007, 318:71-76.
93. Rothwell P.E., et al. Autism-associated neuroligin-3 mutations commonly impair striatal circuits to boost repetitive behaviors. Cell 2014, 158:198-212.
94. Bucan M., et al. Genome-wide analyses of exonic copy number variants in a family-based study point to novel autism susceptibility genes. PLoS Genet. 2009, 5:e1000536.
95. Li J., et al. The MDGA1 gene confers risk to schizophrenia and bipolar disorder. Schizophr. Res. 2011, 125:194-200.
96. Etherton M.R., et al. Mouse neurexin-1alpha deletion causes correlated electrophysiological and behavioral changes consistent with cognitive impairments. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:17998-18003.
97. Coutellier L., et al. Npas4: a neuronal transcription factor with a key role in social and cognitive functions relevant to developmental disorders. PLoS ONE 2012, 7:e46604.
98. Luoni A., et al. Delayed BDNF alterations in the prefrontal cortex of rats exposed to prenatal stress: preventive effect of lurasidone treatment during adolescence. Eur. Neuropsychopharmacol. 2014, 24:986-995.
99. Ramamoorthi K., et al. Npas4 regulates a transcriptional program in CA3 required for contextual memory formation. Science 2011, 334:1669-1675.
100. Talebizadeh Z., et al. Feasibility and relevance of examining lymphoblastoid cell lines to study role of microRNAs in autism. Autism Res. 2008, 1:240-250.
101. Lionel A.C., et al. Rare exonic deletions implicate the synaptic organizer Gephyrin (GPHN) in risk for autism, schizophrenia and seizures. Hum. Mol. Genet. 2013, 22:2055-2066.
102. Dejanovic B., et al. Exonic microdeletions of the gephyrin gene impair GABAergic synaptic inhibition in patients with idiopathic generalized epilepsy. Neurobiol. Dis. 2014, 67:88-96.
103. Feng G., et al. Dual requirement for gephyrin in glycine receptor clustering and molybdoenzyme activity. Science 1998, 282:1321-1324.
104. Etherton M., et al. Autism-linked neuroligin-3 R451C mutation differentially alters hippocampal and cortical synaptic function. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:13764-13769.
105. Jaramillo T.C., et al. Autism-related neuroligin-3 mutation alters social behavior and spatial learning. Autism Res. 2014, 7:264-272.
106. Etherton M.R., et al. An autism-associated point mutation in the neuroligin cytoplasmic tail selectively impairs AMPA receptor-mediated synaptic transmission in hippocampus. EMBO J. 2011, 30:2908-2919.
107. Luo J., et al. Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 2002, 298:425-429.
108. Southwell D.G., et al. Cortical plasticity induced by inhibitory neuron transplantation. Science 2010, 327:1145-1148.
109. Hunt R.F., et al. GABA progenitors grafted into the adult epileptic brain control seizures and abnormal behavior. Nat. Neurosci. 2013, 16:692-697.
110. Aigner S., et al. Human pluripotent stem cell models of autism spectrum disorder: emerging frontiers, opportunities, and challenges towards neuronal networks in a dish. Psychopharmacology 2014, 231:1089-1104.
111. Chanda S., et al. Neurons generated by direct conversion of fibroblasts reproduce synaptic phenotype caused by autism-associated neuroligin-3 mutation. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:16622-16627.
112. Stein J.L., et al. A quantitative framework to evaluate modeling of cortical development by neural stem cells. Neuron 2014, 83:69-86.
113. Rabbani B., et al. The promise of whole-exome sequencing in medical genetics. J. Hum. Genet. 2014, 59:5-15.
114. Peca J., et al. Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature 2011, 472:437-442.
115. Hines R.M., et al. Synaptic imbalance, stereotypies, and impaired social interactions in mice with altered neuroligin 2 expression. J. Neurosci. 2008, 28:6055-6067.
116. Choii, G. and Ko, J. (in press) Gephyrin: a central GABAergic synapse organizer. Exp. Mol. Med.
117. Sun C., et al. Identification and functional characterization of rare mutations of the neuroligin-2 gene (NLGN2) associated with schizophrenia. Hum. Mol. Genet. 2011, 20:3042-3051.
118. Jamain S., et al. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat. Genet. 2003, 34:27-29.
119. Kenny E.M., et al. Excess of rare novel loss-of-function variants in synaptic genes in schizophrenia and autism spectrum disorders. Mol. Psychiatry 2014, 19:872-879.
120. Jenkins A., et al. Identification of candidate single-nucleotide polymorphisms in NRXN1 related to antipsychotic treatment response in patients with schizophrenia. Neuropsychopharmacology 2014, 39:2170-2178.
121. Kim H.G., et al. Disruption of neurexin 1 associated with autism spectrum disorder. Am. J. Hum. Genet. 2008, 82:199-207.
122. Vaags A.K., et al. Rare deletions at the neurexin 3 locus in autism spectrum disorder. Am. J. Hum. Genet. 2012, 90:133-141.
123. Dressman D., et al. X-linked infantile spinal muscular atrophy: clinical definition and molecular mapping. Genet. Med. 2007, 9:52-60.
124. Lesca G., et al. De novo Xq11.11 microdeletion including ARHGEF9 in a boy with mental retardation, epilepsy, macrosomia, and dysmorphic features. Am. J. Med. Genet. A 2011, 155A:1706-1711.
125. Kalscheuer V.M., et al. A balanced chromosomal translocation disrupting ARHGEF9 is associated with epilepsy, anxiety, aggression, and mental retardation. Hum. Mutat. 2009, 30:61-68.
126. Shimojima K., et al. Loss-of-function mutation of collybistin is responsible for X-linked mental retardation associated with epilepsy. J. Hum. Genet. 2011, 56:561-565.
127. Wu K., et al. Glutamate system genes and brain volume alterations in pediatric obsessive-compulsive disorder: a preliminary study. Psychiatry Res. 2013, 211:214-220.
128. Schormair B., et al. PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat. Genet. 2008, 40:946-948.
129. Elia J., et al. Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genes. Mol. Psychiatry 2010, 15:637-646.
130. Pinto D., et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature 2010, 466:368-372.
131. Malhotra D., et al. High frequencies of de novo CNVs in bipolar disorder and schizophrenia. Neuron 2011, 72:951-963.
132. Shyn S.I., et al. Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies. Mol. Psychiatry 2011, 16:202-215.
133. Desrivières S., et al. Single nucleotide polymorphism in the neuroplastin locus associates with cortical thickness and intellectual ability in adolescents. Mol. Psychiatry 2014, Published online February 11, 2014. http://dx.doi.org/10.1038/mp.2013.197.
134. Ringman J.M., et al. Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations. Arch. Neurol. 2012, 69:96-104.
135. Hara Y., et al. A dystroglycan mutation associated with limb-girdle muscular dystrophy. N. Engl. J. Med. 2011, 364:939-946.